equity component. - reply from nick woolf, page-5

PeaceAKKI

I realize it’s a long shot but thought it was worth considering for a couple of reasons

• Since 2008 the Gates Foundation has been providing funding to highly innovative, early-stage projects throughout the world under its Grand Challenges Explorations program.

• Development of affordable vaccines for Third World use is a favoured cause of the Foundation. Hence they have already funded early stage development of a novel vaccine technology delivery system at University of Queensland through this GCE program.

• Likely successful biotech candidates are described as “fledgling” in size.

• The Foundation wants to be able to specify the disease which will be targeted.

• The Foundation has expressed the expectation that chosen biotechs will license the products to global pharmas for profit in first world nations but simultaneously provide low-cost licenses for use in developing nations.

• PYC has had initial success in its identification of vaccine candidates vaccine for Pfizer.

It would appear that the Foundation has already selected its chosen biotechs and if twelve are to be named over the next six months then those biotechs would already be aware and upbeat, knowing that announcement is close.

Sure, PYC is a long shot, but based on these facts, not to be ruled out imo.